EMEKA NNABUIFE: Open Payments
NPI 1497308399 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,141 in 94 payments from 17 companies in 2025. Trend: 2023 $141 · 2024 $2,053 · 2025 $3,141
Food & beverage: $3,141
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $774 |
| ARS Pharmaceuticals Operations, Inc. | 17 | $405 |
| GlaxoSmithKline, LLC. | 8 | $350 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $297 |
| Regeneron Healthcare Solutions, Inc. | 9 | $253 |
| GENZYME CORPORATION | 2 | $181 |
| Grifols USA, LLC | 9 | $150 |
| CSL Behring | 7 | $149 |
| Lilly USA, LLC | 2 | $124 |
| Genentech USA, Inc. | 4 | $111 |
Products named: DUPIXENT, TEZSPIRE, NEFFY, FASENRA, NUCALA, Xembify, AIRSUPRA, Xolair.
Industry payments across TX — which companies pay providers there.
